Radiation Therapy Alone Versus Radiation Therapy Plus Radiofrequency Ablation (RFA)/Vertebral Augmentation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-22

Study Completion Date

2027-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The spread of cancer to the spine is referred to as spine metastasis. Spine metastases are a common complication of cancer and are frequently associated with significant back pain. This study is being done to help improve treatment for back pain caused by spinal metastases by comparing the effectiveness of two standard treatments. These two treatments include radiation therapy (RT) alone versus radiation therapy combined with radiofrequency ablation, with or without vertebral augmentation (PVA/RFA). In addition to RT or RT with PVA/RFA, will be continued with current pain medications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiofrequency Ablation/Bone Augmentation + Radiotherapy vs Radiotherapy Alone

NCT07090122

Spine Metastases Bone Pain

RECRUITING NA

Single- vs. Two-Fraction Spine Stereotactic Radiosurgery for the Treatment of Vertebral Metastases

NCT04218617

Spine Metastases Spine Stereotactic Radiosurgery (sSRS)

RECRUITING PHASE2

Single-fraction IMRT Versus External Beam Radiotherapy for Patients With Spine Bone Metastases

NCT02358720

Pain

UNKNOWN PHASE1/PHASE2

Medical Data Collection for the Evaluation of Radiofrequency Ablation and Cement Augmentation for the Treatment of Secondary Metastases to the Spine

NCT04751422

Metastatic Malignant Neoplasm in the Spine

UNKNOWN

Stereotactic Body Radiotherapy for Spine Tumors

NCT01347307

Spinal Metastases Vertebral Metastases Benign Spinal Tumors +6 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All supportive therapy for optimal medical care will be given during the study period at the discretion of the attending physician(s) within the parameters of the protocol and documented on each site's source documents as concomitant medication.

The study will be adequately powered with 52 patients (35 in the RT plus PVA/RFA arm and 17 in the RT arm). Assuming a 5% ineligibility rate, a death rate of 15%, and a patient non-compliance rate of 15%, the total sample size required would be 80 patients.

Patients will be stratified according to the tumor type (radioresistant \[soft tissue sarcoma, melanoma, and renal cell carcinoma\] versus other types). The treatment allocation scheme described by Zelen (1974) will be used because it balances patient factors. Within each stratum, patients will be randomized in a 2:1 ratio to either image-guided RT plus RFA/PVA or external beam RT alone.

The 2:1 randomization allocation will be used to accommodate increased demand for image-guided RT plus RFA/PVA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oncology Spine Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A study design of 2:1 randomization scheme (RT plus PVA/RFA:RT), the study will be adequately powered with 52 patients (35 in the RT plus PVA/RFA arm and 17 in the RT arm). Assuming a 5% ineligibility rate, a death rate of 15%, and a patient non-compliance rate of 15%, the total sample size required would be 80 patients.

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Radiotherapy

Radiotherapy alone

Group Type OTHER

Radiation Therapy

Intervention Type RADIATION

30 Gy in 10 fractions of 3 Gy each

Radiotherapy plus radiofrequency ablation

Radiotherapy plus radiofrequency ablation / vertebral augmentation(Combination therapy)

Group Type OTHER

Radiation Therapy

Intervention Type RADIATION

30 Gy in 10 fractions of 3 Gy each

Radiofrequency Ablation (RFA)

Intervention Type RADIATION

Radiofrequency Ablation (RFA) / Vertebral Augmentation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radiation Therapy

30 Gy in 10 fractions of 3 Gy each

Intervention Type RADIATION

Radiofrequency Ablation (RFA)

Radiofrequency Ablation (RFA) / Vertebral Augmentation

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient must have localized spine metastasis from the T5 to L5 levels by an imaging study (bone scan, PET, CT, or MRI). Patients can have other visceral metastasis, and radioresistant tumors (including soft tissue sarcomas, melanomas, and renal cell carcinomas) are eligible.
* Zubrod Performance Status 0-3
* History/physical examination within 2 weeks prior to registration
* Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential; Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control;
* MRI (contrast is not required but strongly recommended) of the involved spine within 6 weeks prior to registration to determine the extent of the spine involvement;
* Numerical Rating Pain Scale within 1 week prior to registration; the patient must have a score on the Scale of ≥ 5 for at least one of the planned sites for intervention. Documentation of the patient's initial pain score is required. Patients taking medication for pain at the time of registration are eligible.
* Patients with epidural compression are eligible provided that there is a ≥ 3 mm gap between the spinal cord and the edge of the epidural lesion.
* Patients must provide study specific informed consent prior to study entry.

Exclusion Criteria

* Histologies of myeloma, lymphoma, small-cell lung cancer, germ-cell tumor
* Non-ambulatory patients;
* Frank spinal cord compression or displacement or epidural compression within 3 mm of the spinal cord;
* Patients with rapid neurologic decline;
* Bony retropulsion causing neurologic abnormality;
* Prior radiation to the index spine
* Patients requiring immediate neurosurgical intervention
* Patients receiving concurrent chemotherapy
* Patients needing palliative to more than 2 sites of spinal disease in total

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No